baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC TUR.WAR.OP.END. AXI/ DE000HS5MD24 /

04/06/2024 09:37:24	Chg.-	Bid11:20:42	Ask11:20:42	Underlying	Strike price	Expiration date	Option type
0.1100EUR	-	- Bid Size: 10,000	- Ask Size: 10,000	Atos SE	1.331 -	31/12/2078	Call

GlobeNewswire 28/06 Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...

GlobeNewswire 17/06 Atossa Set to Join Russell 3000® Index Effective June 28, 2024

GlobeNewswire 11/06 Pythian Welcomes Brooks Borcherding as Chief Executive Officer

GlobeNewswire 05/06 Atossa to Present at the Sidoti Small-Cap Investor Conference

GlobeNewswire 30/05 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets

GlobeNewswire 28/05 NetLogistik Wins Partner Leadership Award from Blue Yonder

GlobeNewswire 28/05 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...

GlobeNewswire 16/05 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats

GlobeNewswire 15/05 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...

GlobeNewswire 15/05 Calian Reports Record Results for the Second Quarter

GlobeNewswire 13/05 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 13/05 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing

GlobeNewswire 07/05 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 15/04 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...

GlobeNewswire 11/04 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

GlobeNewswire 09/04 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...

GlobeNewswire 01/04 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 27/03 Calian Announces the Appointment of New President of Advanced Technologies

GlobeNewswire 25/03 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

GlobeNewswire 19/03 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...

GlobeNewswire 18/03 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire 12/03 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...

GlobeNewswire 06/03 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...

GlobeNewswire 22/02 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

HSBC TUR.WAR.OP.END. AXI/ DE000HS5MD24 /

If you wish to receive reply to your feedback, please provide your email address.